• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics Cardiology Classics

The CLARITY trial: Adding clopidogrel to STEMI management [Classics Series]

byAndrew Cheung, MD MBA
December 7, 2013
in Cardiology Classics, The Classics
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

1. The early addition of clopidogrel significantly reduced the incidence of infarct-related arterial re-occlusion within 30 days following myocardial infarction

2. Addition of early clopidogrel improved the outcomes of coronary angiography and decreased the need for early/emergent angiography during the event

3. There were no differences in major or minor bleeding or intracranial hemorrhage incidence between the clopidogrel group and the control group

Original Date of Publication: March 24, 2005

Study Rundown: It is well known that platelet activation and aggregation have a significant role in the initiation and propagation of coronary artery thrombosis. As a result, antiplatelet agents are part of the standard management of acute coronary syndromes. Aspirin, which inactivates the cyclooxygenase enzyme, inhibits platelet aggregation and has been shown to help reduce the rate of reocclusion after myocardial infarction (MI). Clopidogrel is another antiplatelet agent that acts by blocking ADP receptors on platelets. The CLARITY-TIMI 28 trial sought to determine whether early treatment with clopidogrel in addition to standard aspirin and fibrinolytic therapy would produce better outcomes than standard therapy alone in the treatment of ST-elevation MI (STEMI). The study showed that early treatment with clopidogrel had a significant improvement in outcome. The early clopidogrel group had a lower incidence of persistent arterial occlusion or reocclusion, and had improved outcomes on all angiography measures. There was also a significant decrease in the need for early or emergent angiography in the clopidogrel group and a significant decrease in incidence of recurrent MI within 30 days of the first event. No significant difference in 30-day mortality from cardiovascular events was shown, however this study was not powered to assess the impact of intervention on mortality.

In summary, this study showed that early treatment with clopidogrel in addition to standard management of STEMI significantly improves patient outcomes in regard to coronary arterial patency. This study has had meaningful impact on STEMI management and has impacted ACCF and AHA guidelines.

Click to read the study in the NEJM (New England Journal of Medicine)

EvidencePulse™by 2 Minute Medicine®

How does CLARITY apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

Click to read an accompanying editorial in NEJM

Study Author, Dr. Marc Sabatine, MD, MPH, talks to 2 Minute Medicine: Chair of the TIMI group, Associate Professor at Harvard Medical School, Cardiovascular Division. 

“The results [of this study] helped change clinical practice with the adoption of clopidogrel as part of pharmacologic reperfusion therapy for [patients who present with a] STEMI. Clopidogrel is now part of the standard treatment guidelines for management of a STEMI.

[Now], we are conducting the PEGASUS-TIMI 54 [trial], to sort out the duration of P2Y12 inhibition in patients with ACS.”

In-Depth [randomized, controlled study]: The CLARITY-TIMI 28 trial was a large, multicenter, double-blinded, randomized, placebo-controlled trial that enrolled 3,491 patients with an acute STEMI at 319 sites to receive early clopidogrel or placebo along with standard therapy, including aspirin and fibrinolytic agents. Patients between the age of 18-75 years who presented with ST elevation and an episode of chest pain that lasted >20 minutes within 12 hours of randomization were eligible. Patients who had received clopidogrel in the past 7 days, had a history of coronary artery bypass grafting, presented with cardiogenic shock, or who were scheduled to receive coronary angiography within 48 hours regardless of clinical indication were excluded. Eligible patients received a 300 mg loading dose of clopidogrel followed by 75 mg daily maintenance dose and it was continued up to the day of angiography. If a patient did not undergo angiography, it was continued until day 8 or discharge from hospital, whichever was sooner. Patients were followed up to 30 days after randomization. The primary outcome was evidence of infarct-related arterial occlusion on angiography or death/recurrent MI before angiography, day 8 of hospitalization, or hospital discharge.

The study demonstrated that early treatment with clopidogrel caused a 6.7% absolute reduction of the primary end point (21.7% vs. 15%; 95%CI 24-47%, p<0.001). There was no significant difference in the rate of death from any cardiovascular cause between the two groups. The study also demonstrated no significant difference in incidence of major or minor bleeding or intracranial hemorrhage between the two groups (p=0.64, p=0.17, and p=0.38, respectively).

By Milana Bogorodskaya, Evan Chen, and Andrew Cheung, M.D.

Trials since this one

What later trials found on the same question.

  1. 2007

    TRITON In The Classics

    Prasugrel was more effective than clopidogrel in reducing the incidence of recurrent myocardial infarction in patients presenting with acute coronary syndrome, though there was no difference in mortality between the two…

  2. 2007

    COURAGE In The Classics

    Addition of percutaneous cutaneous intervention (PCI) to optimal medical therapy for patients with stable coronary artery disease does not improve mortality or cardiovascular outcomes

10 more since 2005

2MM+ See every trial since CLARITY

2MM+ shows the full timeline of later trials on this question, with what each one found, and lets you save trials to reading lists for rounds, journal club and boards.

See 2MM+ plans Sign in

Citation: Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24;352(12):1179-89. doi: 10.1056/nejmoa050522. Epub 2005 Mar 9. PMID: 15758000.

© 2013 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: PD

Tags: clopidogrelmyocardial infarctionSTEMI

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Cardiology Classics

Previous Post

BMI, waist circumference associated with semen quality

Next Post

Probiotics unrelated to asthma and wheeze prevention in children

Next Post

Probiotics unrelated to asthma and wheeze prevention in children

Classics Series, Landmark Trials in Medicine

The Bogalusa Heart Study: Childhood weight status and cardiovascular risk factors [Pediatrics Classics Series]

Less than one-fifth of patients with hypertension worldwide well controlled

2 Minute Medicine Rewind – December 2 – 8th, 2013

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.